Patents by Inventor Lai-Ming Ching

Lai-Ming Ching has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10888567
    Abstract: Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR1, N or N-oxide; X is CR2, N or N-oxide; Y is CR3, N or N-oxide; Z is CR4, N or N-oxide; and at least one of W, X, Y, and Z is N or N-oxide; and R9 and R10 are as defined. Also described are methods of using such compounds in the treatment of various conditions, such as cancer.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: January 12, 2021
    Assignee: Auckland UniServices Limited
    Inventors: Brian Desmond Palmer, Lai Ming Ching, Swarnalatha Akuratiya Gamage
  • Publication number: 20180244692
    Abstract: Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR1, N or N-oxide; X is CR2, N or N-oxide; Y is CR3, N or N-oxide; Z is CR4, N or N-oxide; and at least one of W, X, Y, and Z is N or N-oxide; and R9 and R10 are as defined. Also described are methods of using such compounds in the treatment of various conditions, such as cancer.
    Type: Application
    Filed: August 25, 2016
    Publication date: August 30, 2018
    Inventors: Brian Desmond Palmer, Lai-Ming Ching
  • Publication number: 20170224701
    Abstract: Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR1, N or N-oxide; X is CR2, N or N-oxide; Y is CR3, N or N-oxide; Z is CR4, N or N-oxide; and at least one of W, X, Y, and Z is N or N-oxide; and R9 and R10 are as defined. Also described are methods of using such compounds in the treatment of various conditions, such as cancer.
    Type: Application
    Filed: August 12, 2015
    Publication date: August 10, 2017
    Inventors: Brian Desmond Palmer, Lai Ming Ching, Swarnalatha Akuratiya Gamage
  • Patent number: 7585893
    Abstract: The present invention relates to the use of compounds such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) for the treatment of cancer, wherein the compounds are administered gastrointestinally, preferably orally. More particularly, the invention is concerned with the use of such compounds, wherein the compound is delivered to the site of action in the patient to be treated in two or more doses.
    Type: Grant
    Filed: April 28, 2005
    Date of Patent: September 8, 2009
    Assignee: Cancer Research Technology Limited
    Inventors: Bruce Charles Baguley, Lai-Ming Ching, Philip Kestell, Liangli Zhao
  • Patent number: 7510830
    Abstract: Methods and compositions are provided for treating cancer, the methods including the step administering, either sequentially or simultaneously, (i) a compound of the xanthenone acetic acid group of compounds, and (ii) at least one compound selected from compounds which modulate TNF production and compounds which act on biochemical pathways leading to TNF synthesis. Compositions include a combination of (i) and (ii) above, together with acceptable pharmaceutical carriers and/or vehicles.
    Type: Grant
    Filed: January 14, 2003
    Date of Patent: March 31, 2009
    Assignee: Cancer Research Technology Limited
    Inventors: Bruce Charles Baguley, Lai-Ming Ching, Martin Philpott
  • Publication number: 20090062377
    Abstract: The present invention relates to synergistic combinations of the compounds of formula I such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and NSAIDs, in particular diclofenac, which have anti-tumour activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing said combinations.
    Type: Application
    Filed: November 3, 2008
    Publication date: March 5, 2009
    Inventors: Liang-Chuan Steve Wang, James William Paxton, Lai-Ming Ching, Bruce Charles Baguley, Philip Kestell
  • Patent number: 7462642
    Abstract: The present invention relates to synergistic combinations of the compounds of formula I such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and NSAIDs, in particular diclofenac, which have anti-tumor activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing said combinations.
    Type: Grant
    Filed: September 22, 2004
    Date of Patent: December 9, 2008
    Assignee: Cancer Research Technology Limited
    Inventors: Liang-Chuan Steve Wang, James William Paxton, Lai-Ming Ching, Bruce Charles Baguley, Philip Kestell
  • Publication number: 20080167272
    Abstract: The present invention concerns certain hydrolytic thalidomide metabolites, combinations thereof with other anti-neoplastic compounds and their use in the treatment of solid tumours.
    Type: Application
    Filed: June 16, 2006
    Publication date: July 10, 2008
    Applicant: Auckland Uniservices Limited
    Inventors: Lai-Ming Ching, Brian D. Palmer
  • Publication number: 20070082937
    Abstract: The present invention relates to synergistic combinations of the compounds of formula (I) such as compounds of the xanthenone acetic acid class such as 5,6dimethylxanthenone-4-acetic acid (DMXAA) and a selective COX-2 inhibitor, in particular rofecoxib, which have anti-tumour activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical formulations containing said combinations.
    Type: Application
    Filed: September 2, 2004
    Publication date: April 12, 2007
    Applicant: Cancer Research Technology Limited
    Inventors: Bruce Baguley, James Paxton, Liang-Chuan Wang, Philip Kestell, Lai-Ming Ching
  • Publication number: 20060009505
    Abstract: The present invention relates to the use of compounds such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) for the treatment of cancer, wherein the compounds are administered gastrointestinally, preferably orally. More particularly, the invention is concerned with the use of such compounds, wherein the compound is delivered to the site of action in the patient to be treated in two or more doses.
    Type: Application
    Filed: April 28, 2005
    Publication date: January 12, 2006
    Inventors: Bruce Baguley, Lai-Ming Ching, Philip Kestell, Liangli Zhao
  • Publication number: 20050131059
    Abstract: The present invention relates to synergistic combinations of the compounds of formula I such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and NSAIDs, in particular diclofenac, which have anti-tumour activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing said combinations.
    Type: Application
    Filed: September 22, 2004
    Publication date: June 16, 2005
    Inventors: Liang-Chuan Wang, James Paxton, Lai-Ming Ching, Bruce Baguley, Philip Kestell
  • Publication number: 20040086498
    Abstract: A method is provided for treating mammals, including humans, with advanced or large-tumour burdens. The method involves administering an immunotherapeautic agent in conjunction with a tumour growth restricting agent, in amounts effective to eradicate any advanced or large tumours present. In preferred embodiments, the immunotherapeautic agent comprises a T-cell co-stimulatory cell adhesion molecule (CAM) or a mammalian expression vector containing DNA which encodes a T-cell co-stimulatory CAM, such as B7.1, and the tumour growth restricting agent is flavone acetic acid, 5,6-dimenthyl-xanthenone-4-acetic acid, or an agent which disrupts the expression or activity of hypoxia-inducible factor-1 (HIF-1).
    Type: Application
    Filed: December 11, 2001
    Publication date: May 6, 2004
    Inventors: Geoffrey W. Krissansen, Jagat Rakesh Kanwar, Lai-Ming Ching
  • Publication number: 20040087611
    Abstract: Methods and composition are provided for treating cancer, the methods including the step a administering, either sequentially or simultaneously, (i) a compound of the xanthenone acetic acid group of compounds, and (ii) at least one compound selected from compounds which modulate TNF production and compounds which act on biochemical pathways leading to TNF synthesis. Compositions include a combination of (i) and (ii) above, together with acceptable pharmaceutical carriers and/or vehicles.
    Type: Application
    Filed: January 14, 2003
    Publication date: May 6, 2004
    Inventors: Bruce Charles Baguley, Lai-Ming Ching, Martin Philpott
  • Publication number: 20030003092
    Abstract: A method is provided for treating mammals, including humans, with advanced or large-tumour burdens. The method involves administering an immunotherapeautic agent in conjunction with a tumour growth restricting agent, in amounts effective to eradicate any advanced or large tumours present. In preferred embodiments, the immunotherapeautic agent comprises a T-cell co-stimulatory cell adhesion molecule (CAM) or a mammalian expression vector containing DNA which encodes a T-cell co-stimulatory CAM, such as B7.1, and the tumour growth restricting agent is flavone acetic acid, 5,6-dimenthyl-xanthenone-4-acetic acid, or an agent which disrupts the expression or activity of hypoxia-inducible factor-1 (HIF-1).
    Type: Application
    Filed: December 11, 2001
    Publication date: January 2, 2003
    Inventors: Geoffrey W. Krissansen, Jagat Rakesh Kanwar, Lai-Ming Ching